When does the patent on saxenda expire?

What is the main patent that protects Saxenda?
Saxenda (liraglutide for weight loss) is protected mainly by U.S. Patent 7,084,441, “Liraglutide and Methods of Using It.” The patent claims the use of liraglutide as a weight‑loss agent and covers the formulation sold as Saxenda.
[1] https://www.drugpatentwatch.com/patents/7044441

When does that patent expire?
The patent was filed on February 14 2007 and is scheduled to expire on February 14 2027.
[1]

Do other patents still block generic competition?
Other older patents on liraglutide have already expired (e.g., the 2004 “Method of treating obesity with GLP‑1 receptor agonists” expired in 2023). Newer secondary patents, such as those covering specific excipients or delivery devices, extend protection for a few years after 2027, but they do not cover the core active ingredient.

What happens when the primary patent expires?
After 2027, competitors can file for generic approval of liraglutide for weight loss, provided no active regulatory exclusivities remain. The FDA’s “BLA” pathway would allow generics once the drug’s patents no longer provide legal protection.

Can similar molecules enter the market earlier?
Biosimilars of the diabetes drug Victoza (liraglutide for type 2 diabetes) have already entered the market in 2023. However, those are for a different indication and may not be interchangeable with Saxenda’s weight‑loss formulation until they clear regulatory pathways for that use.

Does regulatory exclusivity extend beyond the patent?
Saxenda received 6 years of FDA exclusivity for its weight‑loss indication, which began in 2014. That exclusivity expired in 2020, so the only remaining barrier is the patent itself.

Are there any legal challenges that could shorten the patent life?
There have been no major injunctions or litigation that have reduced the term of US 7,084,441. Competitors have pursued patent opposition but the claims remain in force until 2027.

How does this affect pricing?
Until 2027, Novo Nordisk can maintain premium pricing for Saxenda. After the patent ends, generic entrants may drive prices down, but market dynamics will also depend on remaining secondary patents and the competitive landscape.

Sources
[1] DrugPatentWatch – Saxenda (liraglutide) patent details, US 7,084,441.